Literature DB >> 12062371

Developmental changes in the functional characteristics and expression of voltage-gated K+ channel currents in rat aortic myocytes.

Andriy E Belevych1, Richard Beck, Paolo Tammaro, Lucilla Poston, Sergey V Smirnov.   

Abstract

OBJECTIVE: Active control of the arterial diameter by vascular smooth muscle is one of the principle mechanisms by which vessels adapt to a significant rise in blood pressure after birth. Although voltage-gated K+ (Kv) channels play an important role in the regulation of excitation-contraction coupling in arteries, very little is known about postnatal modification of Kv channels. We therefore investigated changes in the functional characteristics and expression of Kv channels in rat aortic myocytes (RAMs) during early postnatal development.
METHODS: Kv currents (I(Kv)) were investigated in single smooth muscle cells freshly dispersed from neonatal (1-3 days) and adult Wistar rat thoracic aorta using the whole-cell patch clamp technique.
RESULTS: I(Kv) in neonates had significantly faster activation kinetics and was inactivated at more positive voltages than I(Kv) in adults (half-inactivation potential -24+/-2 and -40+/-3 mV and slope factor 4.2+/-0.4 and 11.1+/-0.5 mV, respectively). No difference in the steady state activation was found. I(Kv) in neonates was insensitive to a high concentration of tetraethylammonium (TEA, 10 mM) but blocked 4-aminopyridine (4-AP, IC(50)=0.5+/-0.1 mM), whereas I(Kv) in adult RAMs was almost completely abolished by 10 mM TEA and was relatively insensitive to low concentrations of 4-AP. I(Kv) in both age groups was insensitive to charybdotoxin (300 nM) or alpha-dendrotoxin (200 nM). Immunoblot analysis showed that the expression of Kv1.2 alpha-protein decreased and Kv2.1 increased with development.
CONCLUSION: Significant changes in functional characteristics of the native I(Kv) and the expression of particular Kv channel proteins occurred during postnatal vascular development. These changes could play an important role in adaptation to extrauterine life.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12062371     DOI: 10.1016/s0008-6363(02)00227-4

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  6 in total

1.  Stromatoxin-sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter.

Authors:  Xi Zoë Zhong; Khaled S Abd-Elrahman; Chiu-Hsiang Liao; Ahmed F El-Yazbi; Emma J Walsh; Michael P Walsh; William C Cole
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

Review 2.  Voltage-dependent K(+) channels in pancreatic beta cells: role, regulation and potential as therapeutic targets.

Authors:  P E MacDonald; M B Wheeler
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

3.  Pharmacological evidence for a key role of voltage-gated K+ channels in the function of rat aortic smooth muscle cells.

Authors:  Paolo Tammaro; Amy L Smith; Simon R Hutchings; Sergey V Smirnov
Journal:  Br J Pharmacol       Date:  2004-08-23       Impact factor: 8.739

4.  Developmental changes in the expression of voltage-gated potassium channels in the ductus arteriosus of the fetal rat.

Authors:  Cuijiao Wu; Emiko Hayama; Shin-ichiro Imamura; Rumiko Matsuoka; Toshio Nakanishi
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

5.  Ketamine blocks voltage-gated K(+) channels and causes membrane depolarization in rat mesenteric artery myocytes.

Authors:  Seong Hyop Kim; Young Min Bae; Dong Jun Sung; Sang Woong Park; Nam-Sik Woo; Bokyung Kim; Sung Il Cho
Journal:  Pflugers Arch       Date:  2007-03-07       Impact factor: 3.657

6.  TASK-1 channel blockade by AVE1231 increases vasocontractile responses and BP in 1- to 2-week-old but not adult rats.

Authors:  Anastasia A Shvetsova; Dina K Gaynullina; Nadine Schmidt; Peter Bugert; Elena V Lukoshkova; Olga S Tarasova; Rudolf Schubert
Journal:  Br J Pharmacol       Date:  2020-09-24       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.